Short Interest in Gain Therapeutics, Inc. (NASDAQ:GANX) Expands By 9.2%

Gain Therapeutics, Inc. (NASDAQ:GANX) was the recipient of a large increase in short interest during the month of November. As of November 15th, there was short interest totalling 718,700 shares, an increase of 9.2% from the October 31st total of 658,300 shares. Approximately 2.9% of the shares of the company are sold short. Based on an average trading volume of 385,200 shares, the days-to-cover ratio is presently 1.9 days.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on GANX. HC Wainwright reiterated a “buy” rating and set a $8.00 target price on shares of Gain Therapeutics in a research note on Monday, November 25th. Oppenheimer restated an “outperform” rating and set a $8.00 price objective on shares of Gain Therapeutics in a research report on Wednesday, August 14th. Finally, Chardan Capital reiterated a “buy” rating and issued a $6.00 target price on shares of Gain Therapeutics in a research report on Friday, August 9th.

Institutional Investors Weigh In On Gain Therapeutics

Large investors have recently added to or reduced their stakes in the stock. Hohimer Wealth Management LLC bought a new position in shares of Gain Therapeutics during the 2nd quarter valued at approximately $422,000. Warberg Asset Management LLC purchased a new stake in shares of Gain Therapeutics in the second quarter valued at $66,000. Renaissance Technologies LLC lifted its holdings in shares of Gain Therapeutics by 154.2% in the 2nd quarter. Renaissance Technologies LLC now owns 118,700 shares of the company’s stock worth $152,000 after acquiring an additional 72,000 shares during the last quarter. Finally, Geode Capital Management LLC lifted its stake in Gain Therapeutics by 48.0% in the third quarter. Geode Capital Management LLC now owns 271,972 shares of the company’s stock worth $484,000 after purchasing an additional 88,236 shares during the last quarter. 11.97% of the stock is owned by institutional investors.

Gain Therapeutics Stock Performance

Shares of NASDAQ:GANX traded down $0.17 on Tuesday, reaching $1.59. The company’s stock had a trading volume of 356,888 shares, compared to its average volume of 267,327. The company has a 50-day simple moving average of $2.09 and a 200 day simple moving average of $1.70. The company has a debt-to-equity ratio of 0.04, a quick ratio of 2.99 and a current ratio of 2.99. Gain Therapeutics has a 52-week low of $0.89 and a 52-week high of $5.33.

Gain Therapeutics Company Profile

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.